Patient-reported outcomes from the phase III Randomized IMmotion151 trial

atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma

Michael B. Atkins*, Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Cristina Suarez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Howard Gurney, Stephane Oudard, Motohide Uemura, Elaine T. Lam, Carsten Grullich, Caroleen Quach, Susheela Carroll, Beiying Ding, Qian (Cindy) Zhu, Elisabeth Piault-Louis, Christina Schiff & 1 others Bernard Escudier

*Corresponding author for this work

Research output: Contribution to journalArticle


Purpose: Patient-reported outcomes (PRO) were evaluated in the phase III IMmotion151 trial (NCT02420821) to inform overall treatment/disease burden of atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (mRCC). Patients and Methods: Patients were randomized 1:1 to receive atezolizumab 1,200 mg intravenous (i.v.) infusions every 3 weeks (q3w) plus bevacizumab 15 mg/kg i.v. q3w or sunitinib 50 mg per day orally 4 weeks on/2 weeks off. Patients completed the MD Anderson Symptom Inventory (MDASI), National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19), and Brief Fatigue Inventory (BFI) at baseline, q3w during treatment, at end of treatment, and during survival follow-up. Longitudinal and time to deterioration (TTD) analyses for core and RCC symptoms and their interference with daily life, treatment side-effect bother, and health-related quality of life (HRQOL) were evaluated. Results: The intent-to-treat population included 454 and 461 patients in the atezolizumab plus bevacizumab and sunitinib arms, respectively. Completion rates for each instrument were 83% to 86% at baseline and ≥ 70% through week 54. Milder symptoms, less symptom interference and treatment side-effect bother, and better HRQOL at most visits were reported with atezolizumab plus bevacizumab versus sunitinib. The TTD HR (95% CI) favored atezolizumab plus bevacizumab for core (HR, 0.50; 0.40–0.62) and RCC symptoms (HR, 0.45; 0.37–0.55), symptom interference (HR, 0.56; 0.46–0.68), and HRQOL (HR, 0.68; 0.58–0.81). Conclusions: PROs in IMmotion151 suggest lower overall treatment burden with atezolizumab plus bevacizumab compared with sunitinib in patients with treatment-naïve mRCC and provide further evidence for clinical benefit of this regimen.

Original languageEnglish
Pages (from-to)2506-2514
Number of pages9
JournalClinical Cancer Research
Issue number11
Publication statusPublished - 1 Jun 2020

Fingerprint Dive into the research topics of 'Patient-reported outcomes from the phase III Randomized IMmotion151 trial: atezolizumab + bevacizumab versus sunitinib in treatment-naïve metastatic renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this